S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14

Vor Biopharma (VOR) Stock Forecast, Price & News

-0.07 (-1.63%)
(As of 05/18/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
90,544 shs
Average Volume
107,277 shs
Market Capitalization
$158.29 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive VOR News and Ratings via Email

Sign-up to receive the latest news and ratings for Vor Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Vor Biopharma logo

About Vor Biopharma

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Year Founded

Sales & Book Value

Annual Sales


Pretax Margin




Free Float
Market Cap
$158.29 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.82 out of 5 stars

Medical Sector

799th out of 1,418 stocks

Analyst Opinion: 3.4Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Vor Biopharma (NYSE:VOR) Frequently Asked Questions

Is Vor Biopharma a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vor Biopharma in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Vor Biopharma stock.
View analyst ratings for Vor Biopharma
or view top-rated stocks.

When is Vor Biopharma's next earnings date?

Vor Biopharma is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Vor Biopharma

How were Vor Biopharma's earnings last quarter?

Vor Biopharma Inc. (NYSE:VOR) announced its quarterly earnings results on Monday, March, 14th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.06.
View Vor Biopharma's earnings history

What price target have analysts set for VOR?

6 analysts have issued 1-year price targets for Vor Biopharma's stock. Their forecasts range from $6.00 to $46.00. On average, they expect Vor Biopharma's share price to reach $26.71 in the next twelve months. This suggests a possible upside of 533.0% from the stock's current price.
View analysts' price targets for Vor Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Vor Biopharma's key executives?
Vor Biopharma's management team includes the following people:
  • Dr. Robert Ang M.B.A., M.D., MBBS, Pres, CEO & Director (Age 47, Pay $744.46k)
  • Dr. Tirtha Chakraborty Ph.D., Chief Scientific Officer (Age 49, Pay $540.64k)
  • Dr. Christopher Slapak M.D., Chief Medical Officer (Age 63, Pay $590.65k)
  • Dr. Siddhartha Mukherjee DPHIL, M.D., Scientific Founder & Chairman of Scientific Advisory Board (Age 50)
  • Dr. Nathan D. Jorgensen M.B.A., Ph.D., Chief Financial Officer (Age 45)
  • Ms. Tania Philipp, Chief People Officer (Age 50)
  • Dr. Robert G. Pietrusko Pharm.D., Pharm. D., Chief Regulatory & Quality Officer (Age 74)
  • Mr. John C. King, Chief Commercial Officer (Age 46)
  • Dr. Veit Schmelmer Ph.D., Sr. VP of Program & Alliance Management
When did Vor Biopharma IPO?

(VOR) raised $150 million in an initial public offering on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Goldman Sachs, Evercore ISI, Barclays and Stifel served as the underwriters for the IPO.

What is Vor Biopharma's stock symbol?

Vor Biopharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "VOR."

Who are Vor Biopharma's major shareholders?

Vor Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.60%), Paradigm Biocapital Advisors LP (2.38%), Vanguard Group Inc. (1.76%), State Street Corp (0.75%), JPMorgan Chase & Co. (0.49%) and Northern Trust Corp (0.39%). Company insiders that own Vor Biopharma stock include Kush Parmar and Ventures Vi LP 5Am.
View institutional ownership trends for Vor Biopharma

Which major investors are selling Vor Biopharma stock?

VOR stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., JPMorgan Chase & Co., Northern Trust Corp, Qube Research & Technologies Ltd, and Bourgeon Capital Management LLC.
View insider buying and selling activity for Vor Biopharma
or view top insider-selling stocks.

Which major investors are buying Vor Biopharma stock?

VOR stock was acquired by a variety of institutional investors in the last quarter, including Paradigm Biocapital Advisors LP, Bank of Montreal Can, State Street Corp, Ergoteles LLC, and Goldman Sachs Group Inc..
View insider buying and selling activity for Vor Biopharma
or or view top insider-buying stocks.

How do I buy shares of Vor Biopharma?

Shares of VOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vor Biopharma's stock price today?

One share of VOR stock can currently be purchased for approximately $4.22.

How much money does Vor Biopharma make?

Vor Biopharma has a market capitalization of $158.29 million.

How many employees does Vor Biopharma have?

Vor Biopharma employs 135 workers across the globe.

What is Vor Biopharma's official website?

The official website for Vor Biopharma is www.vorbiopharma.com.

How can I contact Vor Biopharma?

The company can be reached via phone at 617 655 6580.

This page was last updated on 5/19/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.